Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 72

1.

Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial.

McNicholas P, Wei Y, Whitcomb J, Greaves W, Black TA, Tremblay CL, Strizki JM.

J Infect Dis. 2010 May 15;201(10):1470-80. doi: 10.1086/652189.

PMID:
20373959
[PubMed - indexed for MEDLINE]
Free Article
2.

Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1).

McNicholas PM, Mann PA, Wojcik L, Phd PQ, Lee E, McCarthy M, Shen J, Black TA, Strizki JM.

J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):222-9. doi: 10.1097/QAI.0b013e3181ff63ee.

PMID:
21209592
[PubMed - indexed for MEDLINE]
3.

Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.

McNicholas P, Vilchez RA, Greaves W, Kumar S, Onyebuchi C, Black T, Strizki JM.

J Clin Virol. 2012 Oct;55(2):134-9. doi: 10.1016/j.jcv.2012.06.021. Epub 2012 Jul 21.

PMID:
22824230
[PubMed - indexed for MEDLINE]
4.

Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.

Ogert RA, Ba L, Hou Y, Buontempo C, Qiu P, Duca J, Murgolo N, Buontempo P, Ralston R, Howe JA.

J Virol. 2009 Dec;83(23):12151-63. doi: 10.1128/JVI.01351-09. Epub 2009 Sep 23.

PMID:
19776131
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.

Irlbeck DM, Amrine-Madsen H, Kitrinos KM, Labranche CC, Demarest JF.

AIDS. 2008 Jul 31;22(12):1425-31. doi: 10.1097/QAD.0b013e32830184ba.

PMID:
18614865
[PubMed - indexed for MEDLINE]
6.

Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.

Ogert RA, Wojcik L, Buontempo C, Ba L, Buontempo P, Ralston R, Strizki J, Howe JA.

Virology. 2008 Apr 10;373(2):387-99. doi: 10.1016/j.virol.2007.12.009. Epub 2008 Jan 10.

PMID:
18190945
[PubMed - indexed for MEDLINE]
Free Article
7.

Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection.

Kümmerle T, Lehmann C, Hartmann P, Wyen C, Fätkenheuer G.

Expert Opin Investig Drugs. 2009 Nov;18(11):1773-85. doi: 10.1517/13543780903357478.

PMID:
19888873
[PubMed - indexed for MEDLINE]
8.

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR; AIDS Clinical Trials Group 5211 Team.

J Infect Dis. 2007 Jul 15;196(2):304-12. Epub 2007 Jun 5.

PMID:
17570119
[PubMed - indexed for MEDLINE]
Free Article
9.

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.

Schürmann D, Fätkenheuer G, Reynes J, Michelet C, Raffi F, van Lier J, Caceres M, Keung A, Sansone-Parsons A, Dunkle LM, Hoffmann C.

AIDS. 2007 Jun 19;21(10):1293-9.

PMID:
17545705
[PubMed - indexed for MEDLINE]
10.

In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.

Tsibris AM, Sagar M, Gulick RM, Su Z, Hughes M, Greaves W, Subramanian M, Flexner C, Giguel F, Leopold KE, Coakley E, Kuritzkes DR.

J Virol. 2008 Aug;82(16):8210-4. doi: 10.1128/JVI.00444-08. Epub 2008 May 21.

PMID:
18495779
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.

Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, Kazmi S, Clarke JR, Johnson GE, Weber JN, Phillips RE.

J Virol. 2003 May;77(10):6041-9.

PMID:
12719595
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.

Demarest JF, Amrine-Madsen H, Irlbeck DM, Kitrinos KM; CCR102881 Clinical Study Team.

Antimicrob Agents Chemother. 2009 Mar;53(3):1116-23. doi: 10.1128/AAC.01055-08. Epub 2008 Dec 15.

PMID:
19075055
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
[PubMed - indexed for MEDLINE]
14.

Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection.

Klibanov OM.

Curr Opin Investig Drugs. 2009 Aug;10(8):845-59. Review.

PMID:
19649929
[PubMed - indexed for MEDLINE]
15.

Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).

Crawford KW, Li C, Keung A, Su Z, Hughes MD, Greaves W, Kuritzkes D, Gulick R, Flexner C; ACTG A5211 Study Team.

J Acquir Immune Defic Syndr. 2010 Apr;53(5):598-605. doi: 10.1097/QAI.0b013e3181c9caac.

PMID:
20071999
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.

Fransen S, Bridger G, Whitcomb JM, Toma J, Stawiski E, Parkin N, Petropoulos CJ, Huang W.

Antimicrob Agents Chemother. 2008 Jul;52(7):2608-15. doi: 10.1128/AAC.01226-07. Epub 2008 Apr 28.

PMID:
18443125
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope.

Kitrinos KM, Amrine-Madsen H, Irlbeck DM, Word JM, Demarest JF; CCR100136 Study Team.

Antimicrob Agents Chemother. 2009 Mar;53(3):1124-31. doi: 10.1128/AAC.01057-08. Epub 2008 Dec 15.

PMID:
19075068
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).

Delaugerre C, Peytavin G, Dominguez S, Marcelin AG, Duvivier C, Gourlain K, Amellal B, Legrand M, Raffi F, Costagliola D, Katlama C, Calvez V.

J Med Virol. 2005 Nov;77(3):345-50.

PMID:
16173015
[PubMed - indexed for MEDLINE]
19.

Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges.

Lenz JC, Rockstroh JK.

Expert Opin Drug Metab Toxicol. 2010 Sep;6(9):1139-50. doi: 10.1517/17425255.2010.510833. Review.

PMID:
20712521
[PubMed - indexed for MEDLINE]
20.

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM.

Clin Infect Dis. 2007 Feb 15;44(4):591-5. Epub 2007 Jan 17. Erratum in: Clin Infect Dis. 2007 May 15;44(10):1399.

PMID:
17243065
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk